Recent advances in antibody-drug conjugates

Area of Science:

• Bioconjugation Chemistry
• Pharmacology
• Oncology Therapeutics

Background:

• Antibody-drug conjugates (ADCs) integrate antibody targeting with potent small-molecule drug payloads.
• Recent advancements in antibody engineering, bioconjugation, linker technology, and payload development have led to significant clinical success and FDA approvals for ADCs.
• The therapeutic landscape for ADCs is rapidly evolving, necessitating a focus on next-generation strategies.

Purpose of the Study:

• To highlight innovations driving the next generation of ADCs.
• To emphasize site-selective conjugation, advanced linker technologies for higher drug-to-antibody ratios (DARs), and novel payload classes.
• To discuss the expanding therapeutic applications of ADCs beyond oncology and identify key challenges.

Main Methods:

• Review of recent innovations in antibody engineering and bioconjugation techniques.
• Analysis of novel linker technologies enabling higher drug-to-antibody ratios (DARs).
• Exploration of emerging payload classes with unique mechanisms of action.

Main Results:

• Site-selective conjugation strategies are crucial for developing next-generation ADCs.
• Linker technologies enabling higher drug-to-antibody ratios (DARs) enhance ADC potency.
• Emerging payload classes offer novel mechanisms of action, expanding therapeutic potential.

Conclusions:

• Innovations in site-selective conjugation, linker technology, and payload design are key to advancing ADCs.
• The scope of ADCs is expanding beyond oncology, presenting new therapeutic opportunities.
• Addressing challenges in ADC development is essential to fully realize their therapeutic potential.